There is no clinically validated dosing table for CJC-1295 or Ipamorelin. However, the general technique of subcutaneous injection – needle size, injection sites, and method of administration – is standard medical knowledge, widely used for peptide injections. This general information can be reliably explained here, separate from any specific dosage recommendations for these particular unapproved compounds.
CJ C-1295 and Ipamorelin Dosage Table
A specific dosing table – in micrograms, millilitres, or injection units – cannot be responsibly provided. No regulatory body has approved a dosing protocol for CJC-1295 or ipamorelin, and the amounts used in published studies were administered under direct clinical supervision for specific research purposes, not as a template for current self-administration.
What is documented is the range used in controlled studies. The main human study on CJC-1295 tested single subcutaneous doses, with researchers identifying 30 and 60 micrograms per kilogram of body weight as eliciting sustained, dose-dependent hormonal responses with good tolerability. This study also tested multiple dosing regimens spread weekly or bi-weekly [1].
For ipamorelin, pharmacokinetic studies in humans have utilised intravenous infusions across a range of doses, with the concentrations required for half-maximal growth hormone stimulation calculated at 214 nanomoles per litre [2]. A separate clinical study in surgical patients used a constant intravenous dose of 0.03 milligrams per kilogram administered twice daily [3].
These numbers describe what was studied clinically, under monitored conditions, for specific research questions. They do not constitute a table intended to be translated into a personal, repeatable schedule of self-injections, nor does any source in the reviewed literature validate a consumer dosing table for any of these compounds, whether used alone or in combination.
How to inject CJC-1295 and ipamorelin
In general pharmacological terms, subcutaneous injection – a method used in the main human trial of CJC-1295 [1] – involves placing the substance into the fatty tissue layer directly beneath the skin, rather than into a muscle or vein. This is the same general category of injection used for many other self-administered peptide and protein drugs, such as insulin.
Common sites for subcutaneous injection used within this broader category of medications include the abdomen (avoiding a five-centimetre radius around the navel), the front or outer thigh, and the back of the upper arm. Site rotation is generally recommended in standard medical practice to reduce irritation or tissue changes at any one specific site.
This is general knowledge regarding injections, applicable to subcutaneous peptides as a category, rather than specific instructions for CJC-1295 or Ipamorelin derived from a dedicated study protocol. Published research on these compounds does not detail site selection guidance aimed at consumers.
What needle size for CJC-1295 and ipamorelin?
The clinical trials reviewed for this article do not specify the size or length of the needle used for administration as needle selection in research settings is a practical, clinical detail rather than a scientific finding published in a resultant research paper.
As a general context, subcutaneous injections of peptide compounds are typically administered with short, thin needles – commonly in the range of 29–31 gauge and about 4–8 millimetres in length. The aim is to reach the subcutaneous fat layer of tissue without penetrating deeper into the muscle. This is standard practice for many subcutaneously administered medications, not a figure specific to studies on CJC-1295 or ipamorelin.
As there is no dedicated needle size study for these compounds, this number should be understood as a general subcutaneous injection convention, not a validated recommendation tied to these specific peptides.
CJC-1295 injection frequency
The injection frequency in published studies varies significantly between these two compounds, arising from their very different durations of action.
CJC-1295, in its long-acting DAC-bound form, was tested with multiple dosing regimens administered solely weekly or bi-weekly. This aligns with its long estimated half-life of approximately 5.8–8.1 days, meaning less frequent dosing was sufficient under research conditions to maintain elevated hormone levels [1].
Ipamorelin, on the other hand, has a significantly shorter half-life of around two hours and elicits a single, sharp pulse of growth hormone release, peaking about 40 minutes post-administration [2], [4]. This is precisely why a clinical trial testing it for post-operative recovery used a twice-daily dosing regimen throughout the treatment period, rather than a weekly schedule [3].
This difference in frequency reflects the distinct pharmacokinetics of each compound, as investigated in their respective clinical trials. However, this is not a validated schedule for the combined use of both compounds administered together, as no published human studies have tested CJC-1295 and Ipamorelin when administered on a shared injection schedule.
Limitations of current evidence
The frequencies and dosages described above are derived from controlled clinical trials using specific routes of administration – subcutaneous for CJC-1295, intravenous for the ipamorelin studies cited – under medical supervision. They do not constitute a validated, general injection or dosing protocol for use.
The needle size and injection site guidance reflect general subcutaneous injection conventions widely used in medicine, rather than discoveries specific to these two compounds. Furthermore, no published studies establish a combined dosing schedule for CJC-1295 and Ipamorelin together.
Disclaimer
This content is for educational purposes only and does not constitute medical advice, dosing guidance, or instructions for self-administration. CJC-1295 and ipamorelin are research compounds and are not approved by the FDA or the European Medicines Agency for any medical use, whether used individually or in combination. The information presented herein regarding dosage, frequency, and injection reflects quantities and methods used in controlled clinical research settings under medical supervision and is not intended to direct or encourage self-administration. There is no validated consumer dosage chart or injection schedule for either of these compounds.
References
[1] Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
[2] Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modelling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402
Beck, D. E., Sweeney, W. B., McCarter, M. D., & Ipamorelin 201 Study Group. (2014). Prospective, randomised, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534. https://doi.org/10.1007/s00384-014-2030-8
[4] Johansen, P. B., Hansen, K. T., Andersen, J. V., & Johansen, N. L. (1998). Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica, 28(11), 1083–1092. https://doi.org/10.1080/004982598238976